Biotech IV Monitor

IRON — Disc Medicine Inc.

$2.8B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Disc Medicine Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.

Next readoutMay 2027in ~6 months
Upcoming readouts31 Phase 3
Market cap$2.8B
Cash & investments$683M~11 quarters at last loss rate
Recent 8-K filings2latest 2026-11-05

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 3 DISC-1459
Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) · NCT06910358
September 2026
Primary data collected

Upcoming readouts

Phase 1/2 DISC-0974
Myelofibrosis; Anemia; Anemia · NCT05320198
May 2027
Recruiting
Phase 2 DISC-3405
Polycythemia Vera (PV) · NCT06985147
July 2027
Ongoing
Phase 2/3 DISC-1459
Erythropoietic Protoporphyria · NCT05883748
June 2028
Enrolling

Cash position

Disc Medicine Inc. reported $683M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $60M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05
8-K Other Events — often topline trial data2026-10-22

Companies working on similar indications

Discussion

No messages yet. If you follow IRON, you can start the conversation.
Track IRON in real time
See live implied volatility for IRON and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on IRON
Contact — questions or corrections about IRON: dukeupt@gmail.com